BIOMAT Database Logo BIOMAT Database Logo

Disposition of zidovudine in obese pregnant women with human immunodeficiency virus type 1 infection. 1996

E P Acosta, and K Schwebke, and K Henry, and C V Fletcher

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011251 Pregnancy Complications, Infectious The co-occurrence of pregnancy and an INFECTION. The infection may precede or follow FERTILIZATION. Complications, Infectious Pregnancy,Infectious Pregnancy Complications,Maternal Sepsis,Pregnancy, Infectious Complications,Sepsis during Pregnancy,Sepsis in Pregnancy,Infectious Pregnancy Complication,Pregnancy Complication, Infectious,Sepsis in Pregnancies,Sepsis, Maternal
D005260 Female Females
D005313 Fetal Death Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH. Fetal Mummification,Fetal Demise,Death, Fetal,Deaths, Fetal,Demise, Fetal,Fetal Deaths,Mummification, Fetal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

E P Acosta, and K Schwebke, and K Henry, and C V Fletcher
Human immunodeficiency virus infection in pregnant women, transmission and zidovudine therapy.
July 2001, European journal of obstetrics, gynecology, and reproductive biology,
E P Acosta, and K Schwebke, and K Henry, and C V Fletcher
A survey of zidovudine use in pregnant women with human immunodeficiency virus infection.
March 1992, The New England journal of medicine,
E P Acosta, and K Schwebke, and K Henry, and C V Fletcher
Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1.
April 1993, The New England journal of medicine,
E P Acosta, and K Schwebke, and K Henry, and C V Fletcher
Myopathy with human immunodeficiency virus type 1 (HIV-1) infection: HIV-1 or zidovudine?
October 1990, Annals of internal medicine,
E P Acosta, and K Schwebke, and K Henry, and C V Fletcher
Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four US states.
May 2001, American journal of obstetrics and gynecology,
E P Acosta, and K Schwebke, and K Henry, and C V Fletcher
Zidovudine reduces intrathecal immunoactivation in patients with early human immunodeficiency virus type 1 infection.
September 1994, Archives of neurology,
E P Acosta, and K Schwebke, and K Henry, and C V Fletcher
Seroprevalence of human immunodeficiency virus type 1 among pregnant women.
July 1992, American journal of perinatology,
E P Acosta, and K Schwebke, and K Henry, and C V Fletcher
Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy.
August 1993, Annals of neurology,
E P Acosta, and K Schwebke, and K Henry, and C V Fletcher
Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
May 1997, The New England journal of medicine,
E P Acosta, and K Schwebke, and K Henry, and C V Fletcher
High Prevalence of Human Papillomavirus Infection among Brazilian Pregnant Women with and without Human Immunodeficiency Virus Type 1.
January 2009, Obstetrics and gynecology international,
Copied contents to your clipboard!